The Company is offering a dedicated support platform called Cycle Vita to provide individualized product support to patients. Ormalvi ™ (dichlorphenamide) has been made available by Cycle ...

Findings showed treatment with delpacibart etedesiran reversed disease progression in DM1 patients based on multiple functional measures. The Food and Drug Administration (FDA) has granted ...

At the time of analysis, no cases of post injection delirium syndrome were reported. A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with ...

The table below is a review of notable updates that occurred in April 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.